Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Therapeutic performance of recombinant antibodies relies on two independent mechanisms: antigen recognition and Fc-mediated antibody effector functions. Interaction of Fc-fragment with different FcR triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity and determines longevity of the antibody in serum. In context of therapeutic antibodies FcγRs play the most important role. It has been demonstrated that the Fc-attached sugar moiety is essential for IgG effector functionality, dictates its affinity to individual FcγRs and determines binding to different receptor classes: activating or inhibitory. In this study, we systematically analyze effector functions of monoclonal IgG1 and its eight enzymatically engineered glycosylation variants. The analysis of interaction of glycovariants with FcRs was performed for single, as well as for antigen-bound antibodies and IgGs in a form of immune complex. In addition to functional properties we addressed impact of glycosylation on the structural properties of the tested glycovariants. We demonstrate a clear impact of glycosylation pattern on antibody stability and interaction with different FcγRs. Consistent with previous reports, deglycosylated antibodies failed to bind all Fcγ-receptors, with the exception of high affinity FcγRI. The FcγRII and FcγRIIIa binding activity of IgG1 was observed to depend on the galactosylation level, and hypergalactosylated antibodies demonstrated increased receptor interaction. Sialylation did not decrease the FcγR binding of the tested IgGs; in contrast, sialylation of antibodies improved binding to FcγRIIa and IIb. We demonstrate that glycosylation influences to some extent IgG1 interaction with FcRn. However, independent of glycosylation pattern the interaction of IgG1 with a soluble monomeric target surprisingly resulted in an impaired receptor binding. Here, we demonstrate, that immune complexes (IC), induced by multimeric ligand, compensated for the decreased affinity of target bound antibody towards FcRs, showing the importance of the IC-formation for the FcR- mediated effector functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“More recently, Dashivets et al. studied enzymatically engineered glycosylation variants and showed that deglycosylated IgG1 had a slightly diminished binding to FcRn, with digalactosylated IgG demonstrating superior binding than monogalactosylated and agalactosylated variants (87).”
From Factors Affecting the FcRn-Mediated Transplacental Transfer of Antibodies and Implications for Vaccination in Pregnancy (2017) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · cited 1×
“[12,65,92] Interaction of the FcRn with IgGs was reported to be independent of the antibody oligosaccharide pattern.”
BackgroundScott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754 · cited 1×
“[85] Sialylated antibodies are believed to be the pro-active species in IVIG (Intravenous Immune Globulin), which suppresses autoantibodymediated inflammation by activating the inhibitory FcγRIIb and downstream negative signaling pathways.”
BackgroundBruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins
Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., & Dwek, R. A. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141702 · Cited by 1,307
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery
Pantoliano, M. W., Petrella, E. C., Kwasnoski, J. D., Lobanov, V. S., Myslik, J., Graf, E., Carver, T., Asel, E., Springer, B. A., Lane, P., et al. (2001) · SLAS Discovery · doi:10.1177/108705710100600609 · Cited by 893
Thermofluor-based high-throughput stability optimization of proteins for structural studies
Ericsson, U. B., Hallberg, B. M., DeTitta, G. T., Dekker, N., & Nordlund, P. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.07.027 · Cited by 839
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 1×
“More than 40 therapeutic mAbs and mAb fragments are approved and prescribed today [1,2], the majority being of the IgG isotype.[3] The IgG molecule consists of two light chains (two domains each) and two heavy chains (four domains each).”
BackgroundKrapp, S., Mimura, Y., Jefferis, R., Huber, R., & Sondermann, P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01250-0 · Cited by 674 · cited 1×
“[84] Impact of terminal sialic acid on the functionality of antibodies remains a controversial issue.”
Background
Research works printed but not linked: 27
- R Kapur, 2014, IgG-effector functions: "The Good, The Bad and The Ugly", Immunol Lett
- RM Anthony, 2012, Novel roles for the IgG Fc glycan, Ann N Y Acad Sci, 1253, 170, 10.1111/j.1749-6632.2011.06305.x · DOI · Paper page
- PM Hogarth, 2012, Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond, Nat Rev Drug Discov, 11, 311, 10.1038/nrd2909 · DOI · Paper page
- XR Jiang, 2011, Advances in the assessment and control of the effector functions of therapeutic antibodies, Nat Rev Drug Discov, 10, 101, 10.1038/nrd3365 · DOI · Paper page
- R Jefferis, 2009, Glycosylation as a strategy to improve antibody-based therapeutics, Nat Rev Drug Discov, 8, 226, 10.1038/nrd2804 · DOI · Paper page
- Y Kaneko, 2006, Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation, Science, 313, 670, 10.1126/science.1129594 · DOI · Paper page
- W Huang, 2012, Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions, J Am Chem Soc, 134, 12308, 10.1021/ja3051266 · DOI · Paper page
- TS Raju, 2008, Terminal sugars of Fc glycans influence antibody effector functions of IgGs, Curr Opin Immunol, 20, 471, 10.1016/j.coi.2008.06.007 · DOI · Paper page
- Y Mimura, 2000, The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms, Mol Immunol, 37, 697, 10.1016/S0161-5890(00)00105-X · DOI · Paper page
- PM Buck, 2013, Consequences of glycan truncation on Fc structural integrity, MAbs, 5, 904, 10.4161/mabs.26453 · DOI
- V Kayser, 2011, Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies, Biotechnol J, 6, 38, 10.1002/biot.201000091 · DOI · Paper page
- S Bohm, 2012, The role of sialic acid as a modulator of the anti-inflammatory activity of IgG, Semin Immunopathol, 34, 443, 10.1007/s00281-012-0308-x · DOI
- Y Kaneko, 2006, Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation, Science, 313, 670, 10.1126/science.1129594 · DOI · Paper page
- RM Anthony, 2012, Novel roles for the IgG Fc glycan, Ann N Y Acad Sci, 1253, 170, 10.1111/j.1749-6632.2011.06305.x · DOI · Paper page
- R Jefferis, 1993, The glycosylation of antibody molecules: functional significance, Glycoconj J, 10, 358
- R Jefferis, 2012, Isotype and glycoform selection for antibody therapeutics, Arch Biochem Biophys, 526, 159, 10.1016/j.abb.2012.03.021 · DOI · Paper page
- PM Buck, 2013, Consequences of glycan truncation on Fc structural integrity, MAbs, 5, 904, 10.4161/mabs.26453 · DOI
- R Jefferis, 2012, Isotype and glycoform selection for antibody therapeutics, Arch Biochem Biophys, 526, 159, 10.1016/j.abb.2012.03.021 · DOI · Paper page
- V Kayser, 2011, Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies, Biotechnol J, 6, 38, 10.1002/biot.201000091 · DOI · Paper page
- Y Mimura, 2000, The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms, Mol Immunol, 37, 697, 10.1016/S0161-5890(00)00105-X · DOI · Paper page
- TS Raju, 2008, Terminal sugars of Fc glycans influence antibody effector functions of IgGs, Curr Opin Immunol, 20, 471, 10.1016/j.coi.2008.06.007 · DOI · Paper page
- K Zheng, 2011, The impact of glycosylation on monoclonal antibody conformation and stability, MAbs, 3, 568, 10.4161/mabs.3.6.17922 · DOI · Paper page
- D Houde, 2010, Post-translational modifications differentially affect IgG1 conformation and receptor binding, Mol Cell Proteomics, 9, 1716, 10.1074/mcp.M900540-MCP200 · DOI · Paper page
- Y Kaneko, 2006, Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation, Science, 313, 670, 10.1126/science.1129594 · DOI · Paper page
- A Lux, 2013, Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs, J Immunol, 190, 4315, 10.4049/jimmunol.1200501 · DOI · Paper page
- DC Roopenian, 2007, FcRn: the neonatal Fc receptor comes of age, Nat Rev Immunol, 7, 715, 10.1038/nri2155 · DOI · Paper page
- MK Leabman, 2013, Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys, MAbs, 5, 896, 10.4161/mabs.26436 · DOI · Paper page
Cited by
Pereira, N. A., Chan, K. F., Lin, P. C., & Song, Z. (2018) · mAbs · doi:10.1080/19420862.2018.1466767 · Cited by 334
“Mutations in the CH2 domain that destroyed the conserved N-glycosylation motif and hence gave rise to aglycosylated Fc resulted in complete loss of binding to most FcgRs except FcgRI.(11) Several approaches have been utilized to increase the affinity between antibody and the FcgRIII.”
BackgroundMethodAffinity of human IgG subclasses to mouse Fc gamma receptors
Dekkers, G., Bentlage, A. E. H., Stegmann, T. C., Howie, H. L., Lissenberg-Thunnissen, S., Zimring, J., Rispens, T., & Vidarsson, G. (2017) · mAbs · doi:10.1080/19420862.2017.1323159 · Cited by 293
Peschke, B., Keller, C. W., Weber, P., Quast, I., & Lünemann, J. D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00646 · Cited by 219
“Two studies reported that Fc-galactosylation results in a slight, albeit not statistically significant increase in FcγRIIIa-binding affinity and ADCC activity (16, 17).”
BackgroundFc Glycan-Mediated Regulation of Placental Antibody Transfer
Jennewein, M. F., Goldfarb, I., Dolatshahi, S., Cosgrove, C., Noelette, F. J., Krykbaeva, M., Das, J., Sarkar, A., Gorman, M. J., Fischinger, S., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.044 · Cited by 212
“Fc-Galactosylation Affects Antibody Binding to FcRn and Other Fc Receptors Contradictory roles for Fc glycosylation on FcRn binding have been reported (Bakchoul et al., 2013; Dashivets et al., 2015; Einarsdottir et al., 2013; Jansen et al., 2016b; Jefferis, 2012), including reports documenting negligible effects of Fc…”
BackgroundInfluentialWilcox, C. R., Holder, B., & Jones, C. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01294 · Cited by 200
“studied enzymatically engineered glycosylation variants and showed that deglycosylated IgG1 had a slightly diminished binding to FcRn, with digalactosylated IgG demonstrating superior binding than monogalactosylated and agalactosylated variants (87).”
Wada, R., Matsui, M., & Kawasaki, N. (2019) · mAbs · doi:10.1080/19420862.2018.1551044 · Cited by 186
“Affinity chromatography For pH gradient human FcRn affinity chromatography, sialylated and galactosylated glycoforms showed longer retention time compared to terminal agalactosylated species (mAb-FA 2G0 and mAb-A2G0) which is consistent with previous reports.(30,31) Partially deglycosylated glycoforms showed shorter r…”
ResultZhou, Q., & Qiu, H. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.11.029 · Cited by 169
Transfer of maternal immunity and programming of the newborn immune system
Jennewein, M. F., Abu-Raya, B., Jiang, Y., Alter, G., & Marchant, A. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0653-x · Cited by 160
“Some studies suggest that FcRn is slightly influenced by glycosylation, with aglycosylated antibodies binding with less affinity than highly sialylated species, but this is not supported by other studies [19, 21].”
Therapeutic monoclonal antibody N-glycosylation – Structure, function and therapeutic potential
Cymer, F., Beck, H., Rohde, A., & Reusch, D. (2017) · Biologicals · doi:10.1016/j.biologicals.2017.11.001 · Cited by 158
Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans
Dekkers, G., Plomp, R., Koeleman, C. A. M., Visser, R., von Horsten, H. H., Sandig, V., Rispens, T., Wuhrer, M., & Vidarsson, G. (2016) · Scientific Reports · doi:10.1038/srep36964 · Cited by 118
“The function of the rest of the glycan features is less clear 14,16,32,33 , although a recent study indicates an additional role of galactose for Fc γ RIIIa binding 34–36 .”
Monitoring of immunoglobulin N- and O-glycosylation in health and disease
de Haan, N., Falck, D., & Wuhrer, M. (2019) · Glycobiology · doi:10.1093/glycob/cwz048 · Cited by 128
Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions
Abdeldaim, D. T., & Schindowski, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102402 · Cited by 129
“The effects are reported to range from a markedly reduced binding of aglycosylated IgG1 to Fc γ RI and C1q up to a complete loss of Fc γ R binding and, therefore, the ability to initiate ADCC for aglycosylated IgG3 [54].”
BackgroundNovel Concepts of Altered Immunoglobulin G Galactosylation in Autoimmune Diseases
Dekkers, G., Rispens, T., & Vidarsson, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00553 · Cited by 123
Mo, J., Yan, Q., So, C., Soden, T., Lewis, M. J., & Hu, P. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b01958 · Cited by 113
The importance of IgG glycosylation—What did we learn after analyzing over 100,000 individuals
Krištić, J., & Lauc, G. (2024) · Immunological Reviews · doi:10.1111/imr.13407 · Cited by 101
“As discussed above, IgG that lacks glycans cannot form functionally relevant interactions with Fc γ receptors, except for Fc γ RI, which is a high-affinity receptor for IgG and retains a higher level of residual binding with glycan-deficient IgG compared to low-affinity Fc γ Rs. 43,52 However, research has demonstrate…”
InfluentialGlycosylation of IgG-Fc: a molecular perspective
Kiyoshi, M., Tsumoto, K., Ishii-Watabe, A., & Caaveiro, J. M. M. (2017) · International Immunology · doi:10.1093/intimm/dxx038 · Cited by 73
Aoyama, M., Hashii, N., Tsukimura, W., Osumi, K., Harazono, A., Tada, M., Kiyoshi, M., Matsuda, A., & Ishii‐Watabe, A. (2019) · mAbs · doi:10.1080/19420862.2019.1608143 · Cited by 79
Kiyoshi, M., Caaveiro, J. M. M., Tada, M., Tamura, H., Tanaka, T., Terao, Y., Morante, K., Harazono, A., Hashii, N., Shibata, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22199-8 · Cited by 77
Majewska, N. I., Tejada, M. L., Betenbaugh, M. J., & Agarwal, N. (2020) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-102419-010001 · Cited by 81
“(32) demonstrated that terminal sialic acid increases binding of antibody to FcγRIIa and FcγRIIb.”
BackgroundStudying protein structure and function by native separation–mass spectrometry
van Schaick, G., Haselberg, R., Somsen, G. W., Wuhrer, M., & Domínguez‐Vega, E. (2022) · Nature Reviews Chemistry · doi:10.1038/s41570-021-00353-7 · Cited by 71
Antibody glycosylation: impact on antibody drug characteristics and quality control
Wang, Z., Zhu, J., & Lu, H. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10368-7 · Cited by 67
“These functions are triggered by the formation of antigen-antibody complexes, which are subsequently recognized by Fcγ receptors (FcγRs).”
BackgroundGlycoform-resolved FcɣRIIIa affinity chromatography–mass spectrometry
Lippold, S., Nicolardi, S., Domínguez‐Vega, E., Heidenreich, A.-K., Vidarsson, G., Reusch, D., Haberger, M., Wuhrer, M., & Falck, D. (2019) · mAbs · doi:10.1080/19420862.2019.1636602 · Cited by 70
Glycan analysis for protein therapeutics
Yang, X., & Bartlett, M. G. (2019) · Journal of Chromatography B · doi:10.1016/j.jchromb.2019.04.031 · Cited by 54
Trzos, S., Link‐Lenczowski, P., & Pocheć, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188838 · Cited by 57
Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity
Wolf, B., Piksa, M., Beley, I., Patoux, A., Besson, T., Cordier, V., Voedisch, B., Schindler, P. A., Stöllner, D., Perrot, L., et al. (2022) · Immunology · doi:10.1111/imm.13481 · Cited by 48
Chia, S., Tay, S. J., Song, Z., Yang, Y., Walsh, I., & Pang, K. T. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114757 · Cited by 49
Conserved FcγR- glycan discriminates between fucosylated and afucosylated IgG in humans and mice
Dekkers, G., Bentlage, A. E. H., Plomp, R., Visser, R., Koeleman, C. A. M., Beentjes, A., Mok, J. Y., van Esch, W. J. E., Wuhrer, M., Rispens, T., et al. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.12.006 · Cited by 49
Xie, L., Zhang, E., Xu, Y., Gao, W., Wang, L., Xie, M. H., Qin, P., Lu, L., Li, S., Shen, P., et al. (2020) · BioDrugs · doi:10.1007/s40259-020-00407-0 · Cited by 47
Hsieh, Y., Aggarwal, P., Cirelli, D. J., Gu, L., Surowy, T. K., & Mozier, N. M. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.12.002 · Cited by 43
Falck, D., Thomann, M., Lechmann, M., Koeleman, C. A. M., Malik, S., Jany, C., Wuhrer, M., & Reusch, D. (2020) · mAbs · doi:10.1080/19420862.2020.1865596 · Cited by 45
Self-citationJansen, B. C., Bondt, A., Reiding, K. R., Scherjon, S. A., Vidarsson, G., & Wuhrer, M. (2016) · Scientific Reports · doi:10.1038/srep34001 · Cited by 38
“…that deglycosylated IgG has a slight diminished binding to FcRn, with digalactosylated IgG showing better binding than monogalac-tosylated and agalactosylated species 15 , other research including in vivo pharmacological studies show an impact of the glycan on the half-life mediated by FcRn 16–18 .”
An Inflammatory Story: Antibodies in Tuberculosis Comorbidities
McLean, M. R., Lu, L. L., Kent, S. J., & Chung, A. W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02846 · Cited by 40
Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization
Foss, S., Grevys, A., Sand, K. M. K., Bern, M., Blundell, P. A., Michaelsen, T. E., Pleass, R. J., Sandlie, I., & Andersen, J. T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.033 · Cited by 39
Immunoglobulin G glycans – Biomarkers and molecular effectors of aging
Krištić, J., Lauc, G., & Pezer, M. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.08.006 · Cited by 38
Rapid screening of IgG quality attributes – effects on Fc receptor binding
Lubbers-Geuijen, K., Oppers‐Tiemissen, C., Egging, D. F., Simons, P. J., Boon, L., Schasfoort, R. B. M., & Eppink, M. H. M. (2017) · FEBS Open Bio · doi:10.1002/2211-5463.12283 · Cited by 36
Human disease glycomics: technology advances enabling protein glycosylation analysis – part 2
Everest‐Dass, A., Moh, E. S. X., Ashwood, C., Shathili, A. M. M., & Packer, N. H. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1448710 · Cited by 36
The importance of IgG N-glycosylation in Health, Disease, and Neonatal hemochromatosis
Thaçi, K., & Anthony, R. M. (2025) · Glycoscience & Therapy · doi:10.1016/j.glycos.2025.100002 · Cited by 33
IgG Fc Glycosylation Patterns of Preterm Infants Differ With Gestational Age
Twisselmann, N., Bartsch, Y. C., Pagel, J., Wieg, C., Hartz, A., Ehlers, M., & Härtel, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03166 · Cited by 29
“In vitro, FcRn has a higher affinity to galactosylated IgG (40).”
BackgroundAntibody mediated activation of natural killer cells in malaria exposed pregnant women
Damelang, T., Aitken, E. H., Hasang, W., López, E., Killian, M., Unger, H. W., Salanti, A., Shub, A., McCarthy, E. A., Kedzierska, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83093-4 · Cited by 27
Gstöttner, C., Hook, M., Christopeit, T., Knaupp, A., Schlothauer, T., Reusch, D., Haberger, M., Wuhrer, M., & Domínguez‐Vega, E. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c03560 · Cited by 28
Self-citationTherapeutic antibodies in oncology: an immunopharmacological overview
Toledo‐Stuardo, K., Ribeiro, C. H., González‐Herrera, F., Matthies, D. J., Roy, M. S. L., Dietz-Vargas, C., Latorre, Y., Campos, I., Guerra, Y., Tello, S., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03814-2 · Cited by 30
“Mutations in the C H 2 domains, which destroy this N-glycosylation motif, give rise to an aglycosylated IgG-Fc and result in complete loss of binding to most FcγR, except FcγRI [190].”
BackgroundLippold, S., Nicolardi, S., Wuhrer, M., & Falck, D. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00698 · Cited by 27
“Affinity chromatography (AC) represents a cell-free physicochemical assay which provides a functional separation and correlates well with surface plasmon resonance (SPR) assays and ADCC assays (Dashivets et al., 2015; Thomann et al., 2015; Wada et al., 2019).”
BackgroundInfluentialImpact of IgG1 N-glycosylation on their interaction with Fc gamma receptors
Cambay, F., Raymond, C., Brochu, D., Gilbert, M., Tu, T.-M., Cantin, C., Lenferink, A. E. G., Grail, M., Henry, O., Crescenzo, G. D., et al. (2020) · Current Research in Immunology · doi:10.1016/j.crimmu.2020.06.001 · Cited by 26
A new approach for identifying positional isomers of glycans cleaved from monoclonal antibodies
Dyukova, I., Faleh, A. B., Warnke, S., Yalovenko, N., Yatsyna, V., Bansal, P., & Rizzo, T. R. (2021) · The Analyst · doi:10.1039/d1an00780g · Cited by 26
IgG Fab Glycans Hinder FcRn-Mediated Placental Transport
Volkov, M., Brinkhaus, M., van Schie, K. A., Bondt, A., Kissel, T., van der Kooi, E. J., Bentlage, A. E. H., Koeleman, C. A. M., de Taeye, S. W., Derksen, N. I. L., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200438 · Cited by 25
The elusive nature of the oligoclonal bands in multiple sclerosis
Kennedy, P. G. E., George, W., & Yu, X. (2023) · Journal of Neurology · doi:10.1007/s00415-023-12081-7 · Cited by 24
“Dashivets et al. also demonstrated that immune complex formation was critical for Fc 𝛾 R -R-mediated effector functions [72].”
Freimoser–Grundschober, A., Rueger, P., Fingas, F., Sondermann, P., Herter, S., Schlothauer, T., Umaña, P., & Neumann, C. (2019) · Journal of Chromatography A · doi:10.1016/j.chroma.2019.460554 · Cited by 20
Self-citationLippold, S., Knaupp, A., de Ru, A. H., Tjokrodirijo, R. T. N., van Veelen, P. A., van Puijenbroek, E., de Taeye, S. W., Reusch, D., Vidarsson, G., Wuhrer, M., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1982847 · Cited by 23
“As mAbs have significantly lower affinity for FcɣRIIIb than for FcɣRIIIa, the separation was optimized starting from the previously reported conditions.(18,20) Two mAbs were used for gradient optimization, representing either low afucosylation/low-affinity glycoforms (mAb1) or glycoengineered high afucosylation/high-a…”
MethodSelf-citationTaylor, S. A., Sharma, S., Remmel, C. A. L., Holder, B. S., Jones, C. E., Marchant, A., & Ackerman, M. E. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac222 · Cited by 20
Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG Transfer in Nonhuman Primates
Rosenberg, Y. J., Ordonez, T., Khanwalkar, U. S., Barnette, P. T., Pandey, S., Backes, I. M., Otero, C. E., Goldberg, B. S., Crowley, A. R., Leib, D. A., et al. (2023) · mBio · doi:10.1128/mbio.00341-23 · Cited by 18
“Thus, analysis in this and prior studies has demonstrated comparable binding of nonglycosylated and glycosylated unmodified and engineered glycoforms of plant-derived VRC01 (37) and other Abs (43) to human FcRn.”
ResultComparison of two glycoengineering strategies to control the fucosylation of a monoclonal antibody
Mishra, N., Spearman, M. A., Donald, L. J., Perreault, H., & Butler, M. (2020) · Journal of Biotechnology · doi:10.1016/j.btecx.2020.100015 · Cited by 20
Gstöttner, C., Knaupp, A., Vidarsson, G., Reusch, D., Schlothauer, T., Wuhrer, M., & Domínguez‐Vega, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.980291 · Cited by 17
“Whereas some reports suggest an increase in binding to the FcgRIIa (23) or a slight increase (20) other reports see either an increase or a decrease depending on the presence of core fucose and bisection (18).”
BackgroundInfluentialSelf-citationCymer, F., Schlothauer, T., Knaupp, A., & Beck, H. (2017) · Bioanalysis · doi:10.4155/bio-2017-0109 · Cited by 18
Self-citationFiebig, D., Bogen, J. P., Carrara, S. C., Deweid, L., Zielonka, S., Grzeschik, J., Hock, B. M., & Kolmar, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.794389 · Cited by 16
“The observed TMs represent a high thermal stability and are within a reasonable range for non-glycosylated human IgG1 antibodies (Garber and Demarest, 2007; Dashivets et al., 2015).”
BackgroundImmunomodulation of Antibody Glycosylation through the Placental Transfer
Gao, C., Chen, Q., Hao, X., & Wang, Q. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316772 · Cited by 21
“FcRn chromatography has revealed that glycosylation patterns can influence FcRn interactions, with deglycosylated IgG exhibiting lower binding [49].”
BackgroundDorokhov, Y. L., Sheshukova, E. V., Kosobokova, E. N., Shindyapina, A. V., Kosorukov, V. S., & Komarova, T. V. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916080058 · Cited by 16
Baumeister, J., Meudt, M., Ebert, S., Rosenau, F., Mizaikoff, B., Blech, M., Aertker, K. M. J., & Higel, F. (2024) · mAbs · doi:10.1080/19420862.2024.2400414 · Cited by 17
“21 22–25 The findings corroborated the theory that a receptor possessing lectin-like characteristics, like the MR, is necessary for the faster clearance of high-mannose containing mAbs.”
Anderson, K. W., Bergonzo, C., Scott, K., Karageorgos, I. L., Gallagher, E. S., Tayi, V. S., Butler, M., & Hudgens, J. W. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167391 · Cited by 18
Inhibition of glycosylation on a camelid antibody uniquely affects its FcγRI binding activity
Krahn, N., Spearman, M. A., Meier, M. R., Dorion-Thibaudeau, J., McDougall, M., Patel, T. R., Crescenzo, G. D., Durocher, Y., Stetefeld, J., & Butler, M. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.09.040 · Cited by 15
Study on antibody Fc-glycosylation for optimal effector functions
Shivatare, V. S., Chuang, P., Tseng, T., Zeng, Y., Huang, H., Gannedi, V., Wu, H., & Wong, C. (2023) · Chemical Communications · doi:10.1039/d3cc00672g · Cited by 15
Henzi, A., Senatore, A., Lakkaraju, A. K., Scheckel, C., Mühle, J., Reimann, R., Sorce, S., Schertler, G. F. X., Toyka, K. V., & Aguzzi, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242137 · Cited by 13
“5 ̊C at pH 7 (Fig 1E), which is similar to the melting temperature of other purified Fc fragments previously reported [27,28] and implies high thermal stability of FT2Fc during storage and handling.”
BackgroundSweet Rules: Linking Glycosylation to Antibody Function
Nimmerjahn, F., & Werner, A. (2021) · Experientia supplementum · doi:10.1007/978-3-030-76912-3_12 · Cited by 14
Sand, K. M. K., Gruber, M., Sandlie, I., Mathiesen, L., Andersen, J. T., & Wadsack, C. (2022) · Placenta · doi:10.1016/j.placenta.2022.07.019 · Cited by 17
Use of 5‐Thio‐L‐Fucose to modulate binding affinity of therapeutic proteins
Zimmermann, M., Nguyen, M., Schultheiss, C. M., Kolmar, H., & Zimmer, A. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27695 · Cited by 12
“Besides FcγR polymorphisms, receptor affinity and, thereby, the biological activity of an antibody depends on the glycosylation of both antibody and receptor (Cambay et al., 2019; Dashivets et al., 2015; Hayes et al., 2014, 2017).”
BackgroundZhu, W., Wang, Y., Lv, L., Wang, H., Shi, W., Liu, Z., Zhou, M., Zhu, J., & Lu, H. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.004 · Cited by 11
Lippold, S., Hook, M., Spick, C., Knaupp, A., Whang, K., Ruperti, F., Cadang, L., Andersen, N., Vogt, A., Grote, M., et al. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03827 · Cited by 12
Self-citationTulika, T., Ruso‐Julve, F., Ahmadi, S., Ljungars, A., Rivera‐de‐Torre, E., Wade, J., Fernández‐Quintero, M. L., Jenkins, T. P., Belfakir, S. B., Ross, G. M. S., et al. (2024) · Structure · doi:10.1016/j.str.2024.07.014 · Cited by 12
Self-citationMahant, A. M., Trejo, F. A. E., Aguilan, J. T., Sidoli, S., Permar, S. R., & Herold, B. C. (2023) · iScience · doi:10.1016/j.isci.2023.107648 · Cited by 10
“To assess this, we quantified the apparent affinity for the FcRn.”
BackgroundBoesch, A. W., Kappel, J. H., Mahan, A. E., Chu, T. H., Crowley, A. R., Osei‐Owusu, N. Y., Alter, G., & Ackerman, M. E. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26545 · Cited by 11
“account for the preferential binding of different IgG-Fc glycoformswith FcγR which presented differences in enrichment as described earlier and in previous studies using FcγR-chromatography (Bolton et al., 2013b;Dashivets et al., 2015; Thomann et al., 2015).”
BackgroundMethodResultInfluentialShibata, H., Harazono, A., Kiyoshi, M., Saito, Y., & Ishii‐Watabe, A. (2025) · BioDrugs · doi:10.1007/s40259-025-00722-4 · Cited by 8
“Galactose addition has also been reported to increase binding affinity to FcγRIIIa [21, 25, 27].”
Gstöttner, C., Lippold, S., Hook, M., Yang, F., Haberger, M., Wuhrer, M., Falck, D., Schlothauer, T., & Domínguez‐Vega, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1347871 · Cited by 9
Self-citationSarsarshahi, S., Bhattacharya, S., Zacharias, Z. R., Kamel, E. S., Houtman, J. C. D., & Nejadnik, M. R. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.103771 · Cited by 8
Malik, S., Grunert, I., von Roman, M. F., Walch, H., Dams, T., Thomann, M., & Falkenstein, R. (2021) · Glycobiology · doi:10.1093/glycob/cwab109 · Cited by 6
Self-citationBajardi-Taccioli, A., Co, C., Bond, C. M., Masci, A., Brantley, T., Xu, C., Bergelson, S., & Feschenko, M. S. (2020) · Analytical Biochemistry · doi:10.1016/j.ab.2020.113842 · Cited by 5
Immunogenicity at delivery after Tdap vaccination in successive pregnancies
Weerdt, L. D., Thiriard, A., Leuridan, E. E., Marchant, A., & Maertens, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1360201 · Cited by 6
Bright, M. R., Curtis, N. C., & Messina, N. L. (2020) · Tuberculosis · doi:10.1016/j.tube.2020.101947 · Cited by 6
Mader, S., Brimberg, L., Soltys, J. N., Bennett, J. L., & Diamond, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01599 · Cited by 6
“glycosylation site (38), however, there are controversial data regarding the effect of altered glycosylation on the transplacental transport (39, 40).”
BackgroundSelective clearance of monoclonal antibodies via the mannose receptor is dependent on glycan pairing
Baumeister, J., Meudt, M., Wei, W., Ebert, S., Rosenau, F., Mizaikoff, B., Blech, M., Chen, L.-Z., & Higel, F. (2026) · Scientific Reports · doi:10.1038/s41598-026-40268-1 · Cited by 6
“As previously described, the symmetrical high-mannose glyco-pair (M5/ M5) relating to F4 showed slightly lower FcRn binding, but this is unlikely to result in a significant difference in PK in vivo 29–31 .”
Voruganti, S., Xu, J., Li, X., Balakrishnan, G., Singh, S. M., Kar, S. R., & Das, T. K. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.09.056 · Cited by 4
Biologics: structural heterogeneity and immunogenicity
Jefferis, R. (2017) · British Journal of Hospital Medicine · doi:10.12968/hmed.2017.78.8.443 · Cited by 5
“Differential addition of other sugars generates a multiplicity of IgG glycoforms that may each modulate the affinity of binding of immune complexes to effector ligands and hence their mode of action (Figure 2) (Jefferis, 2012, 2014; Vidarsson et al, 2014; Dashivets et al, 2015).”
BackgroundQuality Control and Regulatory Aspects for Continuous Biomanufacturing
Forno, G., & Ortí, E. (2017) · Wiley eBooks · doi:10.1002/9783527699902.ch18 · Cited by 5
Human IgG Glycosylation in Inflammation and Inflammatory Disease
Mimura, Y., & Jefferis, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819475-1.00047-x · Cited by 4
Modeling of the Biological Activity of Monoclonal Antibodies Based on the Glycosylation Profile
Czubek, E. E. B., Toboła, P. E., Czubek, B. M., Bednarek, M., Balcerek, J. A., Pietrucha, T., & Jaros, S. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.01.010 · Cited by 3
Quiñonez-Alvarado, M. G., Chávez-Hurtado, P., Caro-Palomera, J. C., Niño-Trejo, O. L., Jiménez-Dolores, J. I., Muñoz‐Villegas, P., Baiza-Durán, L. M., & Quintana-Hau, J. D. D. (2023) · Biologicals · doi:10.1016/j.biologicals.2023.101711 · Cited by 3
Underappreciated layers of antibody-mediated immune synapse architecture and dynamics
Goldberg, B. S., & Ackerman, M. E. (2024) · mBio · doi:10.1128/mbio.01900-24 · Cited by 4
“Cumulatively, differences in isotype and subclass combine with variation in Fc glycosylation (122, 123) to place constraints on Fc spatial orientation (131, 132), modu late receptor engagement (133, 134), and thereby influence the nature of higher-order complex formation (25, 128, 135).”
Bulaon, C. J. I., Jaratsittisin, J., Rattanapisit, K., Suwanchaikasem, P., Guo, S., Boonha, K., Pitaksajjakul, P., Simsom, N., Limprasutr, V., & Phoolcharoen, W. (2025) · Biotechnology Reports · doi:10.1016/j.btre.2025.e00927 · Cited by 5
“Yet, FcRn interaction remains largely intact, explaining the preservation of half-life [43,44].”
Quantifying Carbohydrate Motions Through Solution Measurements: Applications to Immunoglobulin G Fc
Barb, A. W. (2017) · Royal Society of Chemistry eBooks · doi:10.1039/9781782623946-00208 · Cited by 3
Ardini, M., Angelucci, F., Rea, F., Paluzzi, L., Gabriele, F., Palerma, M., Leandro, L. D., Ippoliti, R., & Pitari, G. (2025) · Biology Direct · doi:10.1186/s13062-025-00632-z · Cited by 1
IgG binding characteristics of ferret Fcγ receptors
Ge, X., Stoner, M. R., Weiner, J. A., Hernández, M. E. B., Taher, N. M., Khanwalkar, U. S., Carpenter, M. C., Lee, J., & Ackerman, M. E. (2025) · mAbs · doi:10.1080/19420862.2025.2590248 · Cited by 1
“105,106 Removal of N-glycans of ferret IgG and human IgG1 performed in this study also significantly reduced binding to ferret FcγRs.”
IgG N-glycosylation in autoimmune diseases
Pumpe, C., & Vermeren, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1933960 · Cited by 2
“Showcasing the importance of the N-glycan, binding of aglycosylated IgG to low af fi nity Fc g Rs was negligible/abolished with monomeric IgG and even with immune complexes (15, 115).”
Gstöttner, C., Kaur, H., & Wuhrer, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822318-5.00002-8 · Cited by 1
Friligou, I., Gassner, J., Knoblauch, D., Kagerer, G., Popp, F., Voit, S., Engel, A. M., Leinenbach, A., Steffen, W., Haberger, M., et al. (2021) · Glycobiology · doi:10.1093/glycob/cwab010 · Cited by 1
C1q: A Molecular Bridge to Innate and Adaptive Immunity
Ghebrehiwet, & Kishore, U. (2020) · Frontiers research topics · doi:10.3389/978-2-88963-706-5
Monoclonal Antibody Glycoengineering for Biopharmaceutical Quality Assurance
Gómez, I. A., & del Val, I. J. (2021) · Cell engineering · doi:10.1007/978-3-030-79871-0_6
Faculty Opinions recommendation of Fc Glycan-Mediated Regulation of Placental Antibody Transfer.
Tanaka, S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735977151.793562267
Dent, M. (2021) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/3789
Biosimilars: Shaping the Future of Haematology
Hesp, B. R. (2016) · EMJ Hematology · doi:10.33590/emjhematol/10310413
Development of myeloid cell-based immune profiling on microarrays
Szittner, Z. (2017) · Eötvös Loránd Tudományegyetem · doi:10.15476/elte.2016.056
Impact of the COVID-19 pandemic: SARS-CoV-2-specific IgG antibodies and their vertical transfer
Ward, J. D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95648-2.00017-4
Metadata
- Authors
- Dashivets, T., Thomann, M., Rueger, P., Knaupp, A., Buchner, J., & Schlothauer, T.
- Affiliations
- Center for Integrated Protein Science Munich (DE)
- Roche Pharma AG (Germany) (DE)
- Corresponding author
- Schlothauer, Tilman
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-12-11
- Volume
- 10
- Issue
- 12
- Pages
- e0143520
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4676693
- OpenAlex
- W2190603070
- Cited by
- 101
- References
- 69
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 8 · 2023: 12 · 2022: 7 · 2021: 13 · 2020: 12 · 2019: 10 · 2018: 8 · 2017: 14 · 2016: 7 · 2015: 1
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Roche Innovation Center Zurich
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Keywords
- IgG glycosylation, Fc gamma receptor, antibody effector functions, therapeutic monoclonal antibodies, FcγRI, FcγRIIa, FcγRIIB, FcγRIIIa, neonatal Fc receptor, galactosylation, sialylation, deglycosylation, immune complexes, antibody stability, antibody structure, antibody-drug conjugates
- MeSH terms
- Antibodies, Monoclonal, Antibody Affinity, Antigen-Antibody Complex, Carbohydrate Sequence, Cell Line, Chromatography, Affinity, Galactose, Glycosylation, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Molecular Sequence Data, Protein Binding, Recombinant Proteins, Sialic Acids, Protein Engineering, Gene Expression, Receptors, IgG, Surface Plasmon Resonance, Protein Stability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.